Unearthing individual-level mutation risk patterns

Mutations, which occur continuously in every cell of our bodies, are a key contributor to cancer, ageing, and neurodegeneration. While exposure to mutagenic chemicals, or mistakes in cellular processes during DNA replication contribute to these mutations, the exact distribution and patterns of these changes across human chromosomes have remained a mystery until now.

Dr. Fran Supek, ICREA researcher and head of the Genome Data Science lab at IRB Barcelona, and Marina Salvadores, PhD student in the same laboratory, have delved into the landscape of DNA mutations, unveiling unexpected patterns that differentiate individuals in terms of mutation risk.

Previous work by the laboratory identified a "genomic spellchecker," a DNA repair mechanism devoted to reducing mutation risks in key parts of human chromosomes. Building upon these findings, the current study aimed to determine whether mutation risk varies between individuals and, if so, to identify the mechanisms driving these differences.

"This research not only expands our understanding of the factors influencing mutation rate distribution but it also has significant implications for cancer evolution, therapeutic strategies, and advancements in regenerative medicine," explains Dr. Supek.

A genomic 'big data' analysis

To address these questions, the researchers conducted a comprehensive analysis of genome sequences from over 4,000 tumours from various organs. Unlike previous studies focusing on tissue-specific mutation risks, this study specifically targeted individual differences in susceptibility to mutations.

Employing a genomic "big data" approach, the team used machine learning algorithms to identify recurrent patterns across chromosome segments. They discovered 13 distinct patterns, with 10 corresponding to different types of tissue. Unexpectedly, the remaining three patterns were observed in almost all the tissues, thereby revealing that the density of mutations in specific genes varies significantly between individuals.

Connecting the dots

To understand these unexpected patterns, the researchers examined additional data, including gene expression and genetic aberrations, in cancer cells. The analysis uncovered a surprising correlation between increased cell proliferation and alterations in mutation risks. Disruptions in two crucial tumour-suppressor genes, TP53 and RB1, known to regulate the cell division cycle, were identified as key influencers, causing changes in the risk of mutations across chromosomes.

These chromosome segments not only presented altered mutation risks but also large-scale "remodelling" of usually inactive chromosomal regions.

This remodelling, which is correlated with increased cell proliferation, mirrored the changes in mutation risks, providing unique insight into the interplay between mutations and epigenetic alterations."

Marina Salvadores, first author of the study

Decoding cancer evolution

The implications of this study extend beyond fundamental research. By identifying the cancer-causing genes most affected by changes in mutation risk between individuals, the scientists have provided a roadmap for anticipating the trajectory of cancer evolution. This knowledge is especially relevant for anticipating responses to cancer treatment, as it can help to predict the development of drug-resistance mutations in tumours.

The study also offers valuable insights into the epigenetics of human cells, highlighting that the epigenome undergoes dramatic changes in response to increased or disrupted cell proliferation. This understanding has potential implications for cell reprogramming and regenerative medicine, opening up new avenues for future research and therapeutic interventions.

This study has received funding from the ERC and the Spanish Ministerio de Ciencia e Innovación.

Source:
Journal reference:

Salvadores, M., & Supek, F. (2024). Cell cycle gene alterations associate with a redistribution of mutation risk across chromosomal domains in human cancers. Nature Cancer. doi.org/10.1038/s43018-023-00707-8.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Multitarget stool DNA test shows promise for early colorectal cancer detection